Savant Capital’s Maravai LifeSciences MRVI Stock Holding History

Savant Capital’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-12,216	Closed	-$27K	–	1264
2025 Q1	$27K	Buy	+12,216	New	+$48.3K	﹤0.01%	1066
2024 Q4	–	Sell	-57,828	Closed	-$481K	–	1478
2024 Q3	$481K	Buy	57,828 +3,145	+6%	+$27.2K	﹤0.01%	882
2024 Q2	$392K	Sell	54,683 -78,583	-59%	-$678K	﹤0.01%	882
2024 Q1	$1.16M	Buy	+133,266	New	+$902K	0.01%	498

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MFS

Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return

Point72 (DIFC) Dubai, United Arab Emirates $1.53B AUM 15.83% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Savant Capital's MRVI Position: Q2 2025 in Review

Savant Capital sold out of Maravai LifeSciences (MRVI) in Q2 2025, closing a stake of 12,216 shares — an estimated $27K sold.

Savant Capital first reported a position in MRVI in Q1 2024 and held it in 4 quarters. The position peaked at $1.16M in Q1 2024. 150 funds tracked by Wall St. Rank hold MRVI as of Q2 2025.

Savant Capital reported no remaining Maravai LifeSciences position as of Q2 2025 after selling out during the quarter.
Savant Capital sold 12,216 Maravai LifeSciences shares in Q2 2025, an estimated $27K.
Savant Capital first reported a position in Maravai LifeSciences in Q1 2024 and held it in 4 quarters.
Savant Capital's Maravai LifeSciences position peaked at $1.16M in Q1 2024.
150 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2025.

Based on Savant Capital's 13F filing for Q2 2025, filed 6 Aug 2025.